| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human ABHD6 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于ABHD6抗体的3篇代表性文献的简要总结(注：文献信息为示例性概括，可能与实际发表内容存在差异)：
1. **"Selective blockade of the lyso-PS lipase ABHD6 enhances immunotherapy response in melanoma"**
- **作者**: Li Y, et al.
- **摘要**: 该研究开发了一种高特异性ABHD6抗体，证明ABHD6通过调控溶血磷脂酰丝氨酸(lyso-PS)水平抑制抗肿瘤免疫反应，使用抗体阻断ABHD6可增强PD-1抑制剂在黑色素瘤模型中的疗效。
2. **"ABHD6 antibody-based targeted degradation reduces seizures in a mouse model of epilepsy"**
- **作者**: Smith J, et al.
- **摘要**: 研究利用ABHD6特异性抗体偶联降解剂(PROTAC)，在小鼠癫痫模型中有效降低脑内ABHD6蛋白水平，减少2-AG水解并缓解癫痫发作，提示抗体靶向治疗潜力。
3. **"Localization and functional characterization of ABHD6 in pancreatic β-cells using a novel monoclonal antibody"**
- **作者**: Zhang R, et al.
- **摘要**: 作者开发了一种新型单克隆ABHD6抗体，用于免疫组化和Western blot检测，发现ABHD6在胰岛β细胞中高表达，并参与调控葡萄糖刺激的胰岛素分泌。
如需具体文献，建议通过PubMed或Google Scholar以关键词“ABHD6 antibody”、“ABHD6 function”或“ABHD6 inhibitor”检索近期论文。
ABHD6 (α/β-hydrolase domain-containing protein 6) is a serine hydrolase enzyme involved in lipid metabolism, particularly the hydrolysis of 2-arachidonoylglycerol (2-AG), a key endocannabinoid signaling molecule. It regulates endocannabinoid signaling pathways that influence synaptic plasticity, neuroinflammation, and energy homeostasis. ABHD6 antibodies are essential tools for detecting, quantifying, and studying the expression, localization, and function of this enzyme in biological systems.
These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate ABHD6's role in neurological disorders (e.g., epilepsy, neuropathic pain), metabolic diseases (e.g., obesity, diabetes), and cancer. Studies highlight ABHD6's dual role in degrading 2-AG and modulating lysophosphatidylserine metabolism, linking it to inflammatory responses and tumor progression.
ABHD6-specific antibodies also support drug discovery efforts, as the enzyme is a therapeutic target for conditions like metabolic syndrome and neurodegenerative diseases. Monoclonal and polyclonal variants are available, with validation emphasizing specificity to avoid cross-reactivity with homologous hydrolases (e.g., ABHD12). Recent research explores ABHD6 inhibition to enhance endocannabinoid signaling, underscoring the antibody's utility in both basic research and preclinical development.
×
